Colorectal
Source BioScience Healthcare colorectal cancer portfolio
offers a range of tests which help predict the likely effectiveness
of certain drug therapies. Testing for KRAS is a NICE requirement for identifying which
patients will respond to Erbitux a drug that has recently
been approved for the treatment of metastatic colon cancer
[m CRC] with liver metastasise.
EGFR and BRAF tests are also available to identify which
patients are most likely to respond to the newer anti EGFR
drugs
![[Medical Solutions logo]](/media/25/logo-medical-solutions.png "Medical Solutions"){kind=logo}